Selenium in Radiation Oncology—15 Years of Experiences in Germany †
Abstract
:1. Introduction (Why Should a German Radiation Oncologist Be Interested in Se)
2. Se Measurement in Tumor Patients
3. Clinical Studies on the Effects of Supplemental Se During Radiotherapy
4. Discussion
5. Conclusions
Acknowledgments
Author Contributions
Conflicts of Interest
References
- Micke, O.; Muecke, R.; Buentzel, J.; Kisters, K.; Schaefer, U.; Elements, G.W.G.T. Some more steps on the way to clinical elementology. Trace Elem. Electrolytes 2010, 27, 29–34. [Google Scholar]
- Papp, L.V.; Lu, J.; Holmgren, A.; Khanna, K.K. From selenium to selenoproteins: Synthesis, identity, and their role in human health. Antioxid. Redox Signal. 2007, 9, 775–806. [Google Scholar] [CrossRef] [PubMed]
- Rayman, M.P. The importance of selenium to human health. Lancet 2000, 356, 233–241. [Google Scholar] [CrossRef] [Green Version]
- Schomburg, L.; Schweizer, U.; Kohrle, J. Selenium and selenoproteins in mammals: Extraordinary, essential, enigmatic. Cell Mol. Life Sci. 2004, 61, 1988–1995. [Google Scholar] [CrossRef] [PubMed]
- Rayman, M.P. Selenium and human health. Lancet 2012, 379, 1256–1268. [Google Scholar] [CrossRef]
- Breccia, A.; Badiello, R.; Trenta, A.; Mattii, M. On the chemical radioprotection by organic selenium compounds in vivo. Radiat. Res. 1969, 38, 483–492. [Google Scholar] [CrossRef] [PubMed]
- Diamond, A.M.; Dale, P.; Murray, J.L.; Grdina, D.J. The inhibition of radiation-induced mutagenesis by the combined effects of selenium and the aminothiol wr-1065. Mutat. Res. 1996, 356, 147–154. [Google Scholar] [CrossRef]
- Dorr, W. Effects of selenium on radiation responses of tumor cells and tissue. Strahlenther. Onkol. 2006, 182, 693–695. [Google Scholar] [CrossRef] [PubMed]
- Gehrisch, A.; Dorr, W. Effects of systemic or topical administration of sodium selenite on early radiation effects in mouse oral mucosa. Strahlenther. Onkol. 2007, 183, 36–42. [Google Scholar] [CrossRef] [PubMed]
- Margulies, B.S.; Damron, T.A.; Allen, M.J. The differential effects of the radioprotectant drugs amifostine and sodium selenite treatment in combination with radiation therapy on constituent bone cells, ewing’s sarcoma of bone tumor cells, and rhabdomyosarcoma tumor cells in vitro. J. Orthop. Res. 2008, 26, 1512–1519. [Google Scholar] [CrossRef] [PubMed]
- Mutlu-Turkoglu, U.; Erbil, Y.; Oztezcan, S.; Olgac, V.; Toker, G.; Uysal, M. The effect of selenium and/or vitamin e treatments on radiation-induced intestinal injury in rats. Life Sci. 2000, 66, 1905–1913. [Google Scholar] [CrossRef]
- Patchen, M.L.; MacVittie, T.J.; Weiss, J.F. Combined modality radioprotection: The use of glucan and selenium with wr-2721. Int. J. Radiat. Oncol. Biol. Phys. 1990, 18, 1069–1075. [Google Scholar] [CrossRef]
- Rodemann, H.P.; Hehr, T.; Bamberg, M. Relevance of the radioprotective effect of sodium selenite. Med. Klin. (Munich) 1999, 94 (Suppl. 3), 39–41. [Google Scholar] [CrossRef] [PubMed]
- Schleicher, U.M.; Lopez Cotarelo, C.; Andreopoulos, D.; Handt, S.; Ammon, J. Radioprotection of human endothelial cells by sodium selenite. Med. Klin. (Munich) 1999, 94 (Suppl. 3), 35–38. [Google Scholar] [CrossRef] [PubMed]
- Schueller, P.; Puettmann, S.; Micke, O.; Senner, V.; Schaefer, U.; Willich, N. Selenium influences the radiation sensitivity of c6 rat glioma cells. Anticancer Res. 2004, 24, 2913–2917. [Google Scholar] [PubMed]
- Weiss, J.F.; Hoover, R.L.; Kumar, K.S. Selenium pretreatment enhances the radioprotective effect and reduces the lethal toxicity of wr-2721. Free Radic. Res. Commun. 1987, 3, 33–38. [Google Scholar] [CrossRef] [PubMed]
- Micke, O.; Bruns, F.; Glatzel, M.; Schonekaes, K.; Micke, P.; Mucke, R.; Buntzel, J. Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. Eur. J. Integr. Med. 2009, 1, 19–25. [Google Scholar] [CrossRef]
- Muecke, R.; Schomburg, L.; Buentzel, J.; Kisters, K.; Micke, O.; Oncolo, T.E.E. Selenium or no selenium-that is the question in tumor patients: A new controversy. Integr. Cancer Ther. 2010, 9, 136–141. [Google Scholar] [CrossRef] [PubMed]
- Mucke, R.; Micke, O.; Schonekaes, K.G. Serum selenium levels, glutathione peroxidase activities and serum redox potential levels in patients with untreated non-small cell lung cancer and adenocarcinoma of the rectum. Trace Elem. Electrolytes 2000, 17, 119–123. [Google Scholar]
- Muecke, R.; Klotz, T.; Giedl, J.; Buentzel, J.; Kundt, G.; Kisters, K.; Prott, F.J.; Micke, O. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH. Acta Oncol. 2009, 48, 452–456. [Google Scholar] [CrossRef] [PubMed]
- Muecke, R.; Buentzel, J.; Glatzel, M.; Bruns, F.; Kisters, K.; Prott, F.J.; Schmidberger, H.; Micke, O. Postoperative serum and whole blood selenium levels in patients with squamous cell and adenocarcinomas of the uterus after curative surgical treatment. Trace Elem. Electrolytes 2009, 26, 78–82. [Google Scholar] [CrossRef]
- Meyer, H.A.; Hollenbach, B.; Stephan, C.; Endermann, T.; Morgenthaler, N.G.; Cammann, H.; Kohrle, J.; Jung, K.; Schomburg, L. Reduced serum selenoprotein p concentrations in german prostate cancer patients. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 2386–2390. [Google Scholar] [CrossRef] [PubMed]
- Buntzel, J.; Micke, O.; Kisters, K.; Bruns, F.; Glatzel, M.; Schonekaes, K.; Kundt, G.; Schafer, U.; Mucke, R. Selenium substitution during radiotherapy of solid tumours-laboratory data from two observation studies in gynaecological and head and neck cancer patients. Anticancer Res. 2010, 30, 1783–1786. [Google Scholar] [PubMed]
- Buntzel, J.; Knolle, U.; Garayev, A.; Mucke, R.; Schafer, U.; Kisters, K.; Schonekaes, K.G.; Hunger, R.; Bruns, F.; Glatzel, M.; et al. Trace elements selenium and zinc as tumor markers in patients with advanced head and neck cancer. Trace Elem. Electrolytes 2010, 27, 246–249. [Google Scholar] [CrossRef]
- Muecke, R.; Micke, O.; Schomburg, L.; Buentzel, J.; Kisters, K.; Adamietz, I.A.; Elements, G.W.G.T. Selenium in radiation oncology—Experiences and prospects. Trace Elem. Electrolytes 2011, 28, 168–177. [Google Scholar] [CrossRef]
- Asfour, I.A.; El Shazly, S.; Fayek, M.H.; Hegab, H.M.; Raouf, S.; Moussa, M.A. Effect of high-dose sodium selenite therapy on polymorphonuclear leukocyte apoptosis in non-hodgkin’s lymphoma patients. Biol. Trace Elem. Res. 2006, 110, 19–32. [Google Scholar] [CrossRef]
- Asfour, I.A.; Fayek, M.; Raouf, S.; Soliman, M.; Hegab, H.M.; El-Desoky, H.; Saleh, R.; Moussa, M.A. The impact of high-dose sodium selenite therapy on bcl-2 expression in adult non-hodgkin’s lymphoma patients: Correlation with response and survival. Biol. Trace Elem. Res. 2007, 120, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Asfour, I.A.; El-Tehewi, M.M.; Ahmed, M.H.; Abdel-Sattar, M.A.; Moustafa, N.N.; Hegab, H.M.; Fathey, O.M. High-dose sodium selenite can induce apoptosis of lymphoma cells in adult patients with non-hodgkin’s lymphoma. Biol. Trace Elem. Res. 2009, 127, 200–210. [Google Scholar] [CrossRef] [PubMed]
- Hu, Y.J.; Chen, Y.; Zhang, Y.Q.; Zhou, M.Z.; Song, X.M.; Zhang, B.Z.; Luo, L.; Xu, P.M.; Zhao, Y.N.; Zhao, Y.B.; et al. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol. Trace Elem. Res. 1997, 56, 331–341. [Google Scholar] [CrossRef] [PubMed]
- Sieja, K.; Talerczyk, M. Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. Gynecol. Oncol. 2004, 93, 320–327. [Google Scholar] [CrossRef] [PubMed]
- Weijl, N.I.; Elsendoorn, T.J.; Lentjes, E.G.; Hopman, G.D.; Wipkink-Bakker, A.; Zwinderman, A.H.; Cleton, F.J.; Osanto, S. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: A randomised, double-blind, placebo-controlled study. Eur. J. Cancer 2004, 40, 1713–1723. [Google Scholar] [CrossRef] [PubMed]
- Muecke, R.; Schomburg, L.; Glatzel, M.; Berndt-Skorka, R.; Baaske, D.; Reichl, B.; Buentzel, J.; Kundt, G.; Prott, F.J.; deVries, A.; et al. Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology. Int. J. Radiat. Oncol. 2010, 78, 828–835. [Google Scholar] [CrossRef] [PubMed]
- Muecke, R.; Micke, O.; Schomburg, L.; Glatzel, M.; Reichl, B.; Kisters, K.; Schaefer, U.; Huebner, J.; Eich, H.T.; Fakhrian, K.; et al. Multicenter, phase iii trial comparing selenium supplementation with observation in gynecologic radiation oncology: Follow-up analysis of the survival data 6 years after cessation of randomization. Integr. Cancer Ther. 2014, 13, 463–467. [Google Scholar] [CrossRef] [PubMed]
- Buntzel, J.; Riesenbeck, D.; Glatzel, M.; Berndt-Skorka, R.; Riedel, T.; Mucke, R.; Kisters, K.; Schonekaes, K.G.; Schafer, U.; Bruns, F.; et al. Limited effects of selenium substitution in the prevention of radiation-associated toxicities. Results of a randomized study in head and neck cancer patients. Anticancer Res. 2010, 30, 1829–1832. [Google Scholar] [PubMed]
- Puspitasari, I.M.; Abdulah, R.; Yamazaki, C.; Kameo, S.; Nakano, T.; Koyama, H. Updates on clinical studies of selenium supplementation in radiotherapy. Radiat. Oncol. 2014, 9, 125. [Google Scholar] [CrossRef] [PubMed]
- Lippman, S.M.; Klein, E.A.; Goodman, P.J.; Lucia, M.S.; Thompson, I.M.; Ford, L.G.; Parnes, H.L.; Minasian, L.M.; Gaziano, J.M.; Hartline, J.A.; et al. Effect of selenium and vitamin e on risk of prostate cancer and other cancers: The selenium and vitamin e cancer prevention trial (select). JAMA 2009, 301, 39–51. [Google Scholar] [CrossRef] [PubMed]
- Stranges, S.; Marshall, J.R.; Natarajan, R.; Donahue, R.P.; Trevisan, M.; Combs, G.F.; Cappuccio, F.P.; Ceriello, A.; Reid, M.E. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: A randomized trial. Ann. Intern. Med. 2007, 147, 217–223. [Google Scholar] [CrossRef] [PubMed]
- Micke, O.; Schomburg, L.; Kisters, K.; Buentzel, J.; Huebner, J.; Muecke, R. Selenium and hypertension: Do we need to reconsider selenium supplementation in cancer patients? J. Hypertens. 2013, 31, 1049–1050. [Google Scholar] [CrossRef] [PubMed]
- Muecke, R.; Micke, O.; Schomburg, L.; Kisters, K.; Buentzel, J.; Huebner, J.; Kriz, J. Selenium supplementation in radiotherapy patients: Do we need to measure selenium levels in serum or blood regularly prior radiotherapy? Radiat. Oncol. 2014, 9, 289. [Google Scholar] [CrossRef] [PubMed]
- Muecke, R.; Micke, O.; Schomburg, L.; Buentzel, J.; Adamietz, I.A.; Huebner, J.; Elements, G.W.G.T. Serum selenium deficiency in patients with hematological malignancies: Is a supplementation study mandatory? Acta Haematol. 2014, 132, 256–258. [Google Scholar] [CrossRef] [PubMed]
Effects in | Substances | Examined Criteria | Results | Author |
---|---|---|---|---|
Living rats | Seleno-cystine, seleno-methionine, colloidal selenium, seleno-xanthene, seleno-xanthone, and seleno-chromone | Survival, Leucocytes following exposition to irradiation of 600, 750, and 900 R | Alleviation of mortality and leucopenia | Breccia et al. [6] |
CHO AA8 cells (chinese hamster) | Sodium selenite and aminothiol WR-1065 | Mutation frequency following exposure to 8 Gy | Protection against radiation-induced mutation was observed for both sodium selenite or WR-1065 | Diamond et al. [7] |
Tumor cells and tissues | Sodium selenite | Investigation of effect on the tumor response following selenium supplementation (review) | No detection of increased tumor tolerance | Doerr [8] |
Mouse oral mucosa | Sodium selenite subcuta-neously or locally | Early radiation mucositis following single-dose and fractionated irradiation | Significant positive effect during the initial treatment phase | Gehrisch et al. [9] |
Constituent bone cells and Ewings sarcoma of bone and rhabdomyosarcoma | Amifostine and sodium selenite | Investigation of effects on radioprotection and tumor response | Significant radioprotection to constituent bone cells while not protecting the tumor cells, increased cytotoxicity in nonirradiated and irradiated tumor cells | Margulies et al. [10] |
Rats | Sodium selenite and vitamin E | Radiation-induced intestinal injury | Selenium and/or vitamin E pretreatments ameliorated disturbances in prooxidant-antioxidant balance, this amelioriation has been verified with histopathological findings | Mutlu-Tuerkoglu et al. [11] |
C3H/HeN mice | Amifostine, sodium selenite and glucan | Survival-enhancing and hemopoietic-regenerating effects following exposure to 60 Co radiation | All treatments increased numbers of hemopoietic stem cells, Combined modality treatments were more effective than single-agent treatments | Patchen et al. [12] |
Normal human skin fibroblasts and squamous cell carcinoma cells | Sodium selenite | Quantitative cell culture analyses following single-dose (0 to 7 Gy) and multiple fractionated-dose (5 × 2 Gy) irradiation | Sodium selenite under both radiation exposure conditions positively modulates the radiation response of normal fibroblasts, on the contrary, human tumor cells are not affected by the radioprotective capacity | Rodemann HP et al. [13] |
Human umbilical vein endothelial cells and tumor cells of the HeLa, MIA Paca-2 and SiHa cell line | Sodium selenite | Proliferative activity after single-dose irradiation with 2 or 10 Gy | Sodium selenite can counteract the decrease of proliferative activity caused by irradiation in human endothelial cells, this effect was observed by far stronger in endothelial cells than in tumor cells | Schleicher U et al. [14] |
C6 rat glioma cells | Sodium selenite | Effect after fractionated irradiation | Radiosensitizing effect of selenite | Schueller P et al. [15] |
Male CD2F1 mice | Sodium selenite | Post-irradiation survival | Se-injection alone (1.6 mg/kg) 24 h before cobalt-60 irradiation increased the survival significantly | Weiss JF et al. [16] |
Diagnoses | Parameter | Material | Number | Mean Level | Author |
---|---|---|---|---|---|
Non small cell lung cancer and rectal cancer | Selenium | Serum | n = 20 | 54.4 µg/L (SD = 18.5 µg/L) | Muecke et al. [19] |
Prostate cancer | Selenium | Whole blood | n = 24 | 60.1 µg/L (SD = 17.2 µg/L) | Muecke et al. [20] |
Selenium | Tissue of benign prostate hyperplasia | n = 22 | 198 µg/L (SD = 92.3 µg/L) | ||
Selenium | Benign tissue surrounding the cancer | n = 9 | 139 µg/L (SD = 61.5 µg/L) | ||
Uterine squamous cell cancer and uterine adenocarcinoma | Selenium | Serum | n = 126 | 62.9 µg/L (SD = 18.3 µg/L) | Muecke et al. [21] |
Prostate cancer | Selenium | Serum | n = 90 | 81.4 µg/L (67.9–98.4) | Meyer et al. [22] |
Selenoprotein P | Serum | 2.9 mg/L (1.1–5.5) | |||
Head and neck tumors and carcinomas of the uterus | Selenium | Serum | n = 121 | 59.2 µg/L (SD = 13.5 µg/L) | Buentzel et al. [23] |
Head and neck tumors | Selenium | Serum | n = 100 | 60.6 µg/L (SD = 13.4 µg/L) | Buentzel et al. [24] |
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Muecke, R.; Micke, O.; Schomburg, L.; Buentzel, J.; Kisters, K.; Adamietz, I.A.; On behalf of AKTE. Selenium in Radiation Oncology—15 Years of Experiences in Germany. Nutrients 2018, 10, 483. https://doi.org/10.3390/nu10040483
Muecke R, Micke O, Schomburg L, Buentzel J, Kisters K, Adamietz IA, On behalf of AKTE. Selenium in Radiation Oncology—15 Years of Experiences in Germany. Nutrients. 2018; 10(4):483. https://doi.org/10.3390/nu10040483
Chicago/Turabian StyleMuecke, Ralph, Oliver Micke, Lutz Schomburg, Jens Buentzel, Klaus Kisters, Irenaeus A. Adamietz, and On behalf of AKTE. 2018. "Selenium in Radiation Oncology—15 Years of Experiences in Germany" Nutrients 10, no. 4: 483. https://doi.org/10.3390/nu10040483
APA StyleMuecke, R., Micke, O., Schomburg, L., Buentzel, J., Kisters, K., Adamietz, I. A., & On behalf of AKTE. (2018). Selenium in Radiation Oncology—15 Years of Experiences in Germany. Nutrients, 10(4), 483. https://doi.org/10.3390/nu10040483